• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ovid Therapeutics Inc. (Amendment)

    2/14/24 4:15:31 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OVID alert in real time by email
    SC 13G/A 1 tm246100d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    (Amendment No. 5)

     

    Under the Securities Exchange Act of 1934

     

    OVID THERAPEUTICS INC.

    (Name of Issuer)

     

    COMMON STOCK, $0.001 PAR VALUE

    (Title of Class of Securities)

     

    690469101

    (CUSIP Number)

     

    DECEMBER 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ¨ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    x Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 690469101       Page 2 of 4 Pages

     

     

    1.  

    Name of Reporting Persons

    Jeremy M. Levin

    2.  

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐ (b) ☒

    3.   SEC USE ONLY
    4.  

    Citizenship or Place of Organization

    United States of America

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With:

      5.  

    Sole Voting Power

    6,942,181 (1)

      6.  

    Shared Voting Power

    0

      7.  

    Sole Dispositive Power

    6,942,181 (1)

      8.  

    Shared Dispositive Power

    0

     

    9.  

    Aggregate Amount Beneficially Owned by Each Reporting Person

    6,942,181 (1)

    10.  

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

    ☐

    11.  

    Percent of Class Represented by Amount in Row (9)

    9.4% (2)

    12.  

    Type of Reporting Person (See Instructions)

    IN

     

    (1) Consists of (i) 3,598,467 shares of the Issuer’s common stock held directly by the Reporting Person, (ii) 35,461 shares held by Divo Holdings, LLC, a limited liability company managed by the Reporting Person’s spouse, and (iii) 3,308,253 shares of common stock issuable upon the exercise of stock options within 60 days of December 31, 2023.

     

    (2) This percentage is calculated based upon 70,680,551 outstanding shares of the Issuer’s common stock, as reported in the Issuer’s Form 10-Q Quarterly Report (Commission File No. 001-38085) filed with the Securities and Exchange Commission on November 3, 2023.

     

     

     

    CUSIP No. 690469101       Page 3 of 4 Pages

     

    Item 1(a) Name of Issuer

    Ovid Therapeutics Inc.

     

    Item 1(b) Address of Issuer’s Principal Executive Offices

    441 Ninth Avenue, 14th Floor

    New York, New York 10001

     

    Item 2(a) Name of Person Filing

    Jeremy M. Levin

     

    Item 2(b) Address of Principal Business Office or, if none, Residence

    c/o Ovid Therapeutics Inc.

    441 Ninth Avenue, 14th Floor

    New York, New York 10001

     

    Item 2(c) Citizenship

    United States of America

     

    Item 2(d) Title of Class of Securities

    Common Stock, $0.001 par value

     

    Item 2(e) CUSIP Number

    690469101

     

    Item 3

    Not applicable.

     

    Item 4 Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1

     

    (a) Amount beneficially owned: See Row 9 of cover page for each Reporting Person
    (b) Percent of class: See Row 11 of cover page for each Reporting Person
    (c) Number of shares as to which the person has:
      (i) Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.
      (ii) Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.
      (iii) Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.
      (iv) Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

     

    Item 5 Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

     

    Item 6 Ownership of More than Five Percent of Another Person

    Not applicable.

     

    Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

    Not applicable.

     

    Item 8 Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9 Notice of Dissolution of Group

    Not applicable.

     

    Item 10 Certification

    Not applicable. 

     

     

     

    CUSIP No. 690469101       Page 4 of 4 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024.

     

      By:

    /s/ Jeremy M. Levin

        Jeremy M. Levin

     

     

    Get the next $OVID alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OVID

    DatePrice TargetRatingAnalyst
    6/18/2024Outperform → Perform
    Oppenheimer
    4/30/2024$9.00Buy
    B. Riley Securities
    4/29/2024$9.00Buy
    H.C. Wainwright
    4/5/2024$8.00Outperform
    Wedbush
    12/21/2023$11.00Buy
    BTIG Research
    10/13/2023$8.00Outperform
    Oppenheimer
    8/25/2021$4.50 → $4.00Neutral
    Citigroup
    More analyst ratings

    $OVID
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Papadopoulos Stelios

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      3/4/25 4:44:34 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Papadopoulos Stelios claimed ownership of 200,000 shares (SEC Form 3)

      3 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      3/4/25 4:42:41 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CBFO Rona Jeffrey A sold $2,185 worth of shares (3,902 units at $0.56), decreasing direct ownership by 5% to 67,973 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      2/28/25 4:15:08 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ovid Therapeutics downgraded by Oppenheimer

      Oppenheimer downgraded Ovid Therapeutics from Outperform to Perform

      6/18/24 7:38:14 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Ovid Therapeutics with a new price target

      B. Riley Securities initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00

      4/30/24 8:03:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Ovid Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00

      4/29/24 7:56:55 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      11/14/24 6:01:44 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      11/14/24 4:39:42 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ovid Therapeutics Inc. (Amendment)

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      2/14/24 4:15:31 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Leadership Updates

    Live Leadership Updates

    See more
    • Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

      NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including

      3/3/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer

      NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the appointment of Amanda Banks, M.D., as Chief Development Officer. Dr. Banks will oversee Ovid's clinical development, medical, and regulatory affairs functions as well as drive corporate development strategy and execution in partnership with the Company's leadership team. Dr. Banks brings to Ovid broad and deep experience in neurology, clinical strategy, and business development. Her strategic acumen will serve Ovid at an important juncture for the Company as it determ

      8/8/24 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

      Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid's Scientific Advisory Board (SAB)Neuroscientists Dr. Jamie Maguire of Tufts University and Dr. Jeff Noebels of Baylor College of Medicine, appointed to the SAB to contribute expertise in neurophysiology, hyperexcitability and network effectsThe SAB will advise on the potential application of Ovid's compounds to broader disorders in which they may offer therapeutic promise, including brain conditions caused by hyperexcitability, neurovascular and neuro-inflammatory d

      7/23/24 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

      NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 8:45 AM. ET. A live webcast of the Needham Virtual Healthcare Conference presentation can be accessed through the Events & Presentations section of the company's website at  investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation for approximately 30 da

      4/2/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

      Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinicTopline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, safety, and tolerabilityOV350, Ovid's first program in its KCC2 direct activator library, initiated a first-in-human study in Q1 2025Cash, cash equivalents and marketable securities of $53.1 million as of December 31, 2024, are expected to support operations and development programs into the second half of

      3/11/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

      NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including

      3/3/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    SEC Filings

    See more
    • SEC Form 8-K filed by Ovid Therapeutics Inc.

      8-K - Ovid Therapeutics Inc. (0001636651) (Filer)

      5/2/25 4:14:40 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Ovid Therapeutics Inc.

      PRE 14A - Ovid Therapeutics Inc. (0001636651) (Filer)

      5/2/25 4:09:00 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Ovid Therapeutics Inc.

      10-K/A - Ovid Therapeutics Inc. (0001636651) (Filer)

      4/30/25 4:06:12 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and COO Alexander Margaret A. bought $4,971 worth of shares (6,810 units at $0.73), increasing direct ownership by 24% to 34,935 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      1/29/25 9:18:08 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Levin Jeremy M bought $50,364 worth of shares (18,248 units at $2.76), increasing direct ownership by 0.51% to 3,616,715 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      3/20/24 5:22:00 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Financials

    Live finance-specific insights

    See more
    • Ligand Reports Second Quarter 2024 Financial Results

      Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

      8/6/24 4:01:00 PM ET
      $AGEN
      $AMGN
      $CASI
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations